U

United Laboratories International Holdings Ltd
HKEX:3933

Watchlist Manager
United Laboratories International Holdings Ltd
HKEX:3933
Watchlist
Price: 12.34 HKD 5.11% Market Closed
Market Cap: 22.4B HKD
Have any thoughts about
United Laboratories International Holdings Ltd?
Write Note
United Laboratories International Holdings Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

United Laboratories International Holdings Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

United Laboratories International Holdings Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
U
United Laboratories International Holdings Ltd
HKEX:3933
Current Portion of Long-Term Debt
¥1B
CAGR 3-Years
-9%
CAGR 5-Years
-23%
CAGR 10-Years
-14%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Current Portion of Long-Term Debt
HK$2.5B
CAGR 3-Years
30%
CAGR 5-Years
6%
CAGR 10-Years
4%
Sino Biopharmaceutical Ltd
HKEX:1177
Current Portion of Long-Term Debt
¥8.5B
CAGR 3-Years
66%
CAGR 5-Years
60%
CAGR 10-Years
64%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Current Portion of Long-Term Debt
¥3.3B
CAGR 3-Years
2%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Current Portion of Long-Term Debt
HK$54.5B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

United Laboratories International Holdings Ltd
Glance View

Market Cap
22.4B HKD
Industry
Pharmaceuticals

United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.

Intrinsic Value
21.1 HKD
Undervaluation 42%
Intrinsic Value
Price
U
What is Intrinsic Value?

See Also

What is United Laboratories International Holdings Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1B CNY

Based on the financial report for Jun 30, 2024, United Laboratories International Holdings Ltd's Current Portion of Long-Term Debt amounts to 1B CNY.

What is United Laboratories International Holdings Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-14%

Over the last year, the Current Portion of Long-Term Debt growth was 57%. The average annual Current Portion of Long-Term Debt growth rates for United Laboratories International Holdings Ltd have been -9% over the past three years , -23% over the past five years , and -14% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.